Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant

Authors:

Abstract
Primary central nervous system lymphoma (PCNSL) is a rare extranodal subtype of non-Hodgkin lymphoma (NHL) associated with a high relapse risk without high-dose methotrexate-based induction and subsequent consolidation therapy.1 Commonly used consolidation strategies in patients with PCNSL include whole-brain radiotherapy, nonmyeloablative chemotherapy, and high-dose therapy with autologous hematopoietic cell transplant (AHCT), the latter of which abrogates the risk of chronic neurocognitive toxic effects associated with high-dose whole-brain radiotherapy.2-7 Extrapolating from experience with systemic lymphomas, early AHCT studies for PCNSL used carmustine/etoposide/cytarabine/melphalan (BEAM) conditioning with disappointing disease control and survival results.8-10 More recently, single-arm phase 2 studies demonstrated durable disease control and survival with central nervous system penetrant conditioning regimens, such as thiotepa/busulfan/cyclophosphamide (TBC) and thiotepa/carmustine (TT-BCNU).4,11-17

This publication has 37 references indexed in Scilit: